SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of Shareholders
Werte in diesem Artikel
NEW YORK, Jan. 16, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Enfusion, Inc. (NYSE: ENFN)'s sale to Clearwater Analytics for $5.85 per share in cash and $5.40 per share in Clearwater Class A Common Stock. If you are an Enfusion shareholder, click here to learn more about your rights and options.
Intra-Cellular Therapies, Inc. (NASDAQ: ITCI)'s sale to Johnson & Johnson for $132.00 per share in cash. If you are an Intra-Cellular shareholder, click here to learn more about your rights and options.
Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders. We would handle the action on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email sadeh@halpersadeh.com or zhalper@halpersadeh.com.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
sadeh@halpersadeh.com
zhalper@halpersadeh.com
https://www.halpersadeh.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-investigation-halper-sadeh-llc-investigates-enfn-and-itci-on-behalf-of-shareholders-302353287.html
SOURCE Halper Sadeh LLP
Ausgewählte Hebelprodukte auf Enfusion A
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Enfusion A
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Nachrichten zu Intra-Cellular Therapies Inc
Analysen zu Intra-Cellular Therapies Inc
Datum | Rating | Analyst | |
---|---|---|---|
08.02.2018 | Intra-Cellular Therapies Outperform | RBC Capital Markets | |
15.12.2017 | Intra-Cellular Therapies Buy | Canaccord Adams | |
16.12.2016 | Intra-Cellular Therapies Overweight | Cantor Fitzgerald | |
29.09.2016 | Intra-Cellular Therapies Neutral | SunTrust | |
29.09.2016 | Intra-Cellular Therapies Outperform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
08.02.2018 | Intra-Cellular Therapies Outperform | RBC Capital Markets | |
15.12.2017 | Intra-Cellular Therapies Buy | Canaccord Adams | |
16.12.2016 | Intra-Cellular Therapies Overweight | Cantor Fitzgerald | |
29.09.2016 | Intra-Cellular Therapies Outperform | RBC Capital Markets | |
17.09.2015 | Intra-Cellular Therapies Outperform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
29.09.2016 | Intra-Cellular Therapies Neutral | SunTrust |
Datum | Rating | Analyst | |
---|---|---|---|
Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar. Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Intra-Cellular Therapies Inc nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen